First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
April 24, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
April 15, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
March 18, 2024 07:00 ET
|
First Wave BioPharma, Inc.
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion...
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
March 14, 2024 06:00 ET
|
First Wave BioPharma, Inc.
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave...
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
March 04, 2024 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
February 13, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
December 18, 2023 06:00 ET
|
First Wave BioPharma, Inc.
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent...
Gastrointestinal Therapeutics Market to Reach $64.5 Billion, Globally, by 2032 at 5.0% CAGR: Allied Market Research
September 07, 2023 06:39 ET
|
Allied Market Research
New Castle, Delaware, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Gastrointestinal Therapeutics Market by Drug Class (Biologics, Proton Pump Inhibitors,...